NCT00090623View on ClinicalTrials.gov

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 31, 2004

Study Completion Date

March 31, 2007

Conditions
Macular Degeneration
Interventions
DRUG

rhuFab V2 (ranibizumab)

Trial Locations (1)

Unknown

Trial Information Support Line, Denver

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY